IASLC: Ivonescimab vs Pembrolizumab as First-Line Treatment in …
WEBIn a phase III study conducted in China, the bispecific antibody ivonescimab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with the PD-1 inhibitor pembrolizumab as a first-line treatment of PD-L1–positive advanced non–small cell lung cancer (NSCLC), according to Zhou et al.
Promising Anti-Tumor Activity and Safety of Ivonescimab in …
WEB5 days ago · No patients receiving ivonescimab plus FOLFOXIRI and one patient receiving ivonescimab plus ligufalimab plus FOLFOXIRI permanently discontinued drug treatment due to treatment-related adverse...
Ivonescimab Outperforms Pembrolizumab as Frontline Therapy in …
WEBSep 8, 2024 · Ivonescimab produced a significant improvement in PFS vs pembrolizumab as frontline therapy in patients with PD-L1–positive advanced NSCLC.
Ivonescimab outperforms pembrolizumab in study for first-line …
WEBSep 8, 2024 · Data from a Phase 3 study has revealed that ivonescimab demonstrates a statistically significant and clinically meaningful improvement in progression-free survival compared to pembrolizumab for...
Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated …
WEBSep 8, 2024 · Ivonescimab has been approved in China for treating EGFR mutated locally advanced or metastatic non-squamous NSCLC patients who have progressed after EGFR TKI treatment. It is the world's...
Ivonescimab Tops Pembro in Advanced PD-L1-Positive NSCLC
WEBSep 8, 2024 · Ivonescimab (AK112) is a novel, potentially first-in-class investigational bi-specific antibody that targets programmed death 1 (PD-1) and vascular endothelial growth factor (VEGF) developed by...
Summit therapy beat Merck blockbuster Keytruda in late-stage …
WEBSep 8, 2024 · The Summit drug, an antibody called ivonescimab, reduced the risk of tumor progression by 49% compared to Keytruda, according to data released here at the World Conference on Lung Cancer.
Akeso Published First-Ever Efficacy Data for PD-1/VEGF ... - BioSpace
WEB5 days ago · For first-line treatment of MSS/pMMR mCRC with ivonescimab, either alone or in combination with ligufalimab and FOLFOXIRI, the objective response rate (ORR) was 88.2%, and the disease control rate (DCR) was 100%.
Ivonescimab Monotherapy Decisively Beats Pembrolizumab …
WEBMay 30, 2024 · Ivonescimab, known as AK112 is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis...
Ivonescimab combined with chemotherapy in patients with EGFR …
WEBMay 29, 2024 · Background: Ivonescimab (AK112/SMT112) is a anti-PD-1/VEGF bispecific antibody. Previous phase I/II clinical studies have shown potential efficacy of ivonescimab in NSCLC patients with EGFR mutations who had failed prior EGFR-TKIs therapies.